PO-0838: Validation of a bioeffect model for boost focal therapy for prostate cancer using I-125 brachytherapy  by Haworth, A. et al.
S318  2nd ESTRO Forum 2013 
 
Purpose/Objective: The PTV is a remnant of the days of conformal 
radiotherapy. Its adequacy expired when IMRT became available to 
provide non-uniform dose distributions, and the field of radiation 
therapy has lived under its yoke for long enough. Joe Deasy dubbed it 
`Paranoid Target Volume' during ESTRO 2012. In this paper we 
illustrate the scale of this paranoia which is both of geometrical and 
biological nature. 
Materials and Methods: We considered the situation of a 5cm 
diameter spherical Clinical Target Volume, and assumed isotropic 
systematic and random geometric errors during dose delivery with 
3mm SD. A 3.2mm SD Gaussian penumbra shape was assumed, leading 
to a 10mm PTV margin according to the Van Herk recipe. To simulate 
the effect of a nearby OAR the maximum dose to a 5cm sphere placed 
at various distances was limited to a maximum of 50% of the 
prescribed dose of 60Gy. Probabilistic optimization accounting for 
systematic and random errors was performed using a 3mm dose grid 
and optimizing each dose voxel independently, to obtain idealized 
dose distributions that are easy to understand. As target objectives 
we either used the minimum dose at 90% confidence level or the 
Webb/Nahum TCP equation (N=5x107, α=0.34±0.08). As dose limiting 
function the mean dose to the entire grid was used. A custom cost 
function suppressed shells with dose increasing outwards (`horns'). 
Optimized distributions were evaluated in terms of expected TCP and 
confidence levels on minimum CTV dose using Monte Carlo based plan 
evaluation.  
Results: The OAR could be brought in to a distance of 5mm, locally 
pushing the 95% isodose to within 2.5mm of the surface of the CTV, 
while preserving a 90% confidence of receiving at least 95% of dose 
prescription in 99% of the CTV (Fig 1a). To compensate for the loss of 
coverage towards the OAR, the dose expanded in other directions, 
shifting the 95% isodose level outwards by about 1.5mm while 
increasing the integral dose by less than 8%. This illustrates the 
limited value of the PTV as a geometrical tool to control target 
coverage in case of conflicting OAR constraints. When optimizing TCP 
up to the same level provided by the PTV dose (66%), integral dose 
could be decreased by 35% (Fig 1b, dotted line). Alternatively, TCP 
could be increased to 93% when keeping the same integral dose as the 
PTV dose (Fig 1b, dashed line). These results illustrate the incapability 
of the PTV to assess the limited importance of underdosage near the 
PTV surface, where the probability of CTV presence is small. 
Knowledge of dose-effect relations is required for this assessment, but 
the PTV concept in incapable of incorporating such knowledge even if 
it is available.  
 
 
Conclusions: The PTV lacks geometrical flexibility and biological 
sophistication. Probability and/or biology based dose optimization can 
prevent planning conflicts introduced by rigid application of a PTV 
margin, and will provide a much improved balance between tumor 
control and normal tissue complications. 
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Purpose/Objective: Low dose rate brachytherapy is a highly 
efficacious treatment for low risk prostate cancer. The commonly 
prescribed ablative dose of 145 Gy however, may be more than 
required resulting in increased toxicity for little gain in tumour 
control. We propose a bioeffect model may be used to determine the 
optimal dose distribution to maximise tumour control and minimise 
toxicity. The model may be used with parameters derived from 
biological imaging, to target an ablative dose at known regions of 
significant tumour burden with a lower, but still therapeutic dose to 
lower burden regions. 
Materials and Methods: To validate the previously published bioeffect 
model[1], data from 423 patients with low risk prostate cancer 
treated with I-125 radioactive seed implant at 3 Australian institutions 
was analysed. To apply the bioeffect model, each patient’s prostate 
volume was mathematically divided into 12 sub-sections. The DVH was 
determined for each subsection and used to calculate the tumour 
control probability by applying a unique tumour cell density to each 
subsection based on published foci distributions. Biochemical failure 
was defined using the Phoenix definition. A cut-point in calculated 
TCP, which could provide significant prediction of FFbF, was sought. 
The sensitivity of the model to variations in tumour doubling time and 
hypoxia was investigated. 
Results: When TCP values were above and below 0.62, the 5-year 
FFbF were 93.7% (95%CI90.4-96.4%) and 88.8% (95%CI 81.3-94.5%) 
respectively (p=0.004). Using published data related to tumour 
doubling time and hypoxia, the model predicted dose escalation 
beyond 10-25% in tumour bearing regions was of no further benefit. 
Conclusions: Using post-implant dosimetry data and published data 
the TCP model was able to predict for FFbF. Using the cut-point 
values derived from this study and tumour specific data from 
multiparametric imaging suggests this model may be used to plan non-
uniform dose distributions that will maintain high rates of FFbF with 
reduced treatment related toxicity.  
1. Haworth A, Ebert M, Waterhouse D, et al., Assessment of I-125 
prostate implants by tumor bioeffect. Int J Radiat Oncol Biol Phys, 
2004; 59(5): 1405-13. 
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Purpose/Objective: To introduce microscopic biological concepts in 
treatment planning and use the results to optimize dose, modality, 
and radiation sensitizing agents and use these plans to predict results. 
This paper introduces the concepts and applies it to the treatment of 
tumors with variable oxygenation levels.  
Materials and Methods:  
1) Results from microdosimetric simulations are parameterized as a 
function of modality (electrons,protons), energy, and oxygenation. 
The parameterization based on a combination of cumulative cauchy 
functions and first order rational functions, allows real-time 
conversion of dose calculation to DNA-damage in single (SSB) and 
double strand break (DSB) modes. The dose calculations can come 
from any off the shelf commercial treatment planning system.  
2) The model is applied to hypothetical mono-energetic electron 
deposition treatments as well as a clinical four-field box treatment 
using a clinical 6MV beam. The spatial distribution of the oxygenation 
is modeled using a spatial normal distribution of oxygen levels with a 
center having no access to oxygen. The spatial oxygen distribution (P') 
is registered to the dose distribution matrix (D). For a realistic beam 
with energy depositing spectrum Ψ(E) (obtained by simulation) the 
damage matrix is provided by:  
 
 
